Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled eight approved products for partners, which include leading biopharmaceutical companies.

News
Aug 21, 2014 Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients »
Jul 31, 2014 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 »
Jul 22, 2014 Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets »
Jun 19, 2014 Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients »
Contact Nektar Investor Relations
Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs
415-482-5585

Jodi Sievers
Associate Director, Investor & Corporate Communications
415-482-5593

Contact
Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877)290-2261
(201)680-6578
www.computershare.com/investor
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide